An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-01

Study Completion Date

2030-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

the Quality of Life Assessment of Lung Cancer Patients in China

NCT01914120

Lung Cancer

UNKNOWN

Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients

NCT07170059

Lung Cancer

NOT_YET_RECRUITING

Survival Outcomes of Lung Cancer

NCT03647098

Lung Cancer

RECRUITING

A Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy

NCT07288710

Lung Cancer (Diagnosis) Lobectomy Sublobar Resection

RECRUITING

Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer

NCT07166003

Lung Cancer, Non-Small Cell Immunotherapy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

LUNG CANCER

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccination group

Lung cancer patients receive 23-valent pneumonia vaccine

23-valent pneumococcal vaccine

Intervention Type BIOLOGICAL

Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine

Unvaccinated group

Lung cancer patients have not received the 23-valent pneumococcal vaccine

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

23-valent pneumococcal vaccine

Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients \>=18 years of age;
2. Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
3. Never received pneumococcal vaccine